Quick Answer
Dogwood Therapeutics, Inc. reported Stockholders Equity of $74.90 million for the year ending 2025.
- Dogwood Therapeutics, Inc. showed an increase of +839.8% in Stockholders Equity from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $27.11 million | Q2 2021: $22.86 million | Q3 2021: $18.88 million | Q1 2022: $10.67 million | Q2 2022: $7.14 million | Q3 2022: $9.22 million | Q1 2023: $5.97 million | Q2 2023: $4.69 million | Q3 2023: $4.76 million | Q1 2024: $2.65 million | Q2 2024: $3.14 million | Q3 2024: $949.4 thousand | Q1 2025: $7.09 million | Q2 2025: $6.88 million | Q3 2025: $7.26 million.
- Over the full 7 years of available data (2019 to 2025), Dogwood Therapeutics, Inc.'s Stockholders Equity has grown by 1,592.7%.
- Historical annual values: Fiscal year 2025: $74.90 million | Fiscal year 2024: -$10.12 million | Fiscal year 2023: $3.81 million | Fiscal year 2022: $7.33 million | Fiscal year 2021: $14.50 million | Fiscal year 2020: $29.94 million | Fiscal year 2019: -$5.02 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: